{"protocolSection":{"identificationModule":{"nctId":"NCT02841579","orgStudyIdInfo":{"id":"MedOPP112"},"secondaryIdInfos":[{"id":"2015-004828-66","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"MedSIR","class":"OTHER"},"briefTitle":"Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M","officialTitle":"A Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of Osimertinib (AZD9291) in First-line Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC and Concomitant EGFR T790M Mutation at Time of Diagnosis","acronym":"AZENT"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-09-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-12","type":"ACTUAL"},"completionDateStruct":{"date":"2020-02-14","type":"ACTUAL"},"studyFirstSubmitDate":"2016-07-08","studyFirstSubmitQcDate":"2016-07-21","studyFirstPostDateStruct":{"date":"2016-07-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-02-10","resultsFirstSubmitQcDate":"2025-01-02","resultsFirstPostDateStruct":{"date":"2025-01-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-02","lastUpdatePostDateStruct":{"date":"2025-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MedSIR","class":"OTHER"},"collaborators":[{"name":"AstraZeneca","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The primary goal is to evaluate the efficacy of osimertinib (AZD9291), in terms of the objective response rate in patients with advanced non-squamous NSCLC with EGFR mutations and the EGFR T790M mutation at diagnosis as defined by RECIST 1.1 criteria.\n\nSafety and efficacy will also be measured.","detailedDescription":"Naïve patients ≥ 18 years of age with histological confirmation of locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with an activating EGFR mutation and concomitant T790M mutation. Evidence of measurable or evaluable metastatic disease is required.\n\nPrimary objective:\n\n* To evaluate the efficacy of osimertinib (AZD9291), in terms of the objective response rate in patients with advanced non-squamous NSCLC with EGFR mutations and the EGFR T790M mutation at diagnosis as defined by RECIST 1.1 criteria.\n\nSecondary objectives:\n\n* To determine the safety and tolerability profile of osimertinib (AZD9291), measured using the number and severity of AEs entered into the Case Report Form (CRF); chemistry, blood count, vital signs, physical examination, weight, ECG and performance status (S).\n* To determine other efficacy parameters such as progression-free survival (PFS), overall survival (OS), time to treatment failure (TTF), duration of response (DOR), disease control rate (DCR), and tumor shrinkage (TS).\n* To correlate the parameters of clinical response efficacy documented with the EGFR mutational status.\n* To carry out a longitudinal analysis of EGFR mutations (including the T790M mutation) in plasma and serum.\n* To determine levels of BIM mRNA as well as mRNA levels of other biomarkers related to EGFR TKI response and determine whether they are predictors of treatment response.\n* To identify mechanisms of acquired resistance to osimertinib (AZD9291); mutations at the site of covalent binding to the drug (C797) or other mutations in tissue or blood.\n\nType of study: Multicenter, international, single-arm, open-label, non-controlled phase IIa clinical study.\n\nTreatment: Patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":22,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Osimertinib","type":"EXPERIMENTAL","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.","interventionNames":["Drug: Osimertinib"]}],"interventions":[{"type":"DRUG","name":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.","armGroupLabels":["Osimertinib"],"otherNames":["AZD9291"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"Defined as the percentage of patients who achieved complete response \\[CR\\] and partial response \\[PR\\] to treatment in accordance to the revised RECIST guidelines (version 1.1) for target lesions: CR, disappearance of all target lesions; PR: at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"Through study completion. From baseline up to approximately 28 months."}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"Time from the start of treatment to the time of death due to any cause.","timeFrame":"Through study completion. From baseline up to 41 months."},{"measure":"Duration of Response (DoR)","description":"Time from the first documented response to documented disease progression or death, in accordance with RECIST 1.1 criteria.","timeFrame":"Through study completion. From baseline up to 41 months."},{"measure":"Disease Control Rate","description":"Percentage of patients with complete response, partial response or stable disease for a minimum of 24 weeks, assessed in accordance with the modified Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, during all study period from baseline up to 78 weeks from the time of the first administration dose","timeFrame":"Through study completion. From baseline up to 41 months."},{"measure":"Tumor Shrinkage","description":"Number of patients that presented tumor shrinkage","timeFrame":"Through study completion. From baseline up to 41 months."},{"measure":"Overall Plasma EGFR Mutation Status at Baseline","description":"Percentage of patients with a positive sensitizing EGFR mutation in plasma at baseline","timeFrame":"Baseline"},{"measure":"Overall Plasma Acquired Resistance to Osimertinib (AZD9291)","description":"Percentage of patients who develop anti-drug mutations in plasma","timeFrame":"Through study completion. From baseline up to 41 months."},{"measure":"Number of Participants With Grade 3 or 4 Adverse Events and SAEs","description":"Patient safety and adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) of the U.S. National Cancer Institute (NCI), version 4. Adverse event(s) are those which, according to the protocol or in the opinion of the investigator, can cause serious or permanent damage or which rule out further treatment with the study drug. Grade 3 means severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 means life-threatening consequences; urgent intervention indicated.","timeFrame":"Through study completion. From baseline up to 41 months."},{"measure":"Progression-free Survival","description":"Defined as the period of time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1.","timeFrame":"Through study completion. From baseline up to 41 months."},{"measure":"Overall Plasma EGFR Mutation Status at Two Weeks After the First Study Dose","description":"Measured by percentage of patients with a positive sensitizing EGFR mutation in plasma two weeks after the first study dose","timeFrame":"Two weeks after the first study dose"},{"measure":"Overall Plasma EGFR Mutation Status at Disease Progression","description":"Measured by percentage of patients with a positive sensitizing EGFR mutation in plasma at disease progression","timeFrame":"At the time of disease progression confirmed radiologically or clinically, up to 78 weeks"},{"measure":"Plasma EGFR Thr790Met Mutation Status at Baseline","description":"Measured by percentage of patients with EGFR Thr790Met mutation in plasma at baseline","timeFrame":"At baseline"},{"measure":"Plasma EGFR Thr790Met Mutation Status at Two Weeks After the First Study Dose","description":"Measured by percentage of patients with EGFR Thr790Met mutation in plasma at two weeks after the first study dose","timeFrame":"Two weeks after the first study dose"},{"measure":"Plasma EGFR Thr790Met Mutation Status at Disease Progression","description":"Measured by percentage of patients with EGFR Thr790Met mutation in plasma at disease progression","timeFrame":"At the time of disease progression confirmed radiologically or clinically, up to 78 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Patients with histological confirmation of locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with an activating EGFR mutation and concomitant T790M mutation who are not candidates for local curative treatment.\n* Patients with a M1a stage according to the TNM version 7 including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease that is not a candidate for curative treatment (including patients who progress after chemoradiotherapy in stage III disease).\n* Patients with a EGFR deletion or mutation in exon 19, exon 21 (L858R, L861Q) or exon 18 (G719X) and concomitant T790M mutation before treatment confirmed centrally.\n* ECOG (Eastern Cooperative Oncology Group) performance status less than or equal to 2.\n* Existence of measurable or evaluable disease (as per RECIST 1.1 criteria). Patients with asymptomatic and stable brain metastases are eligible for the study.\n* Possibility of obtaining sufficient tissue sample, via a biopsy or surgical resection of the primary tumor or metastatic tumor tissue, within the 60 days prior to study entry.\n* Life expectancy ≥12 weeks.\n* Adequate hematologic function:\n\n  * Absolute neutrophil count (ANC) \\> 1.5 x 109/L\n  * platelet count \\> 100.0 x109/L\n  * hemoglobin \\> 9.0 g/dL (\\> 6.2 mmol/L).\n* Adequate coagulation: INR ≤ 1.5.\n* Adequate liver function\n* Adequate renal function.\n* Capacity to swallow, patient capable of completing treatment and accessible, ensuring proper follow-up.\n* Patients able to complete study and within geographical proximity allowing for adequate follow-up.\n* Resolution of all acute toxic effects of previous anti-cancer therapy (which can only be adjuvant or neoadjuvant) or surgical interventions not exceeding grade ≤ 1 according to the NCI CTCAE version 4.0 (except for alopecia or other side effects that the investigator does not consider to be a risk to patient safety).\n* All men or women of childbearing potential must use a contraception method during the study treatment and for at least 12 months after the last dose of the study drug.\n* Signed and dated informed consent form\n\nExclusion Criteria:\n\n* Locally advanced lung cancer candidate for curative treatment through radical surgery and/or radio(chemo)therapy.\n* Patients diagnosed with another lung cancer subtype, patients with mixed NSCLC with predominantly squamous cell cancer, or with any small-cell lung cancer component.\n* Patients with a EGFR deletion or mutation in exon 19, exon 21 (L858R, L861Q) or exon 18 (G719X) and concomitant T790M mutation before treatment that have not been confirmed centrally.\n* Patients who have received prior antineoplastic treatment for advanced disease.\n* Second active neoplasia\n* Patients with just one measurable or evaluable tumor lesion that has been resected or irradiated prior to their enrollment in the study.\n* Medical history of Interstitial Lung Disease (ILD) induced by drugs, radiation pneumonitis requiring steroid treatment or any evidence of clinically active ILD.\n* Corrected QT Interval (QTc) \\>470 msec, obtained from 3 ECGs at rest, using the QTc value determined according to the clinical screening ECG machine.\n* Any clinically significant abnormality in ECG rhythm, conduction or morphology at rest.\n* Any factor that increases the risk of QTc prolongation or risk of irregular heartbeat or sudden inexplicable death under the age of 40 in first-degree relatives or any concomitant medications that prolong the QT interval.\n* Uncontrolled, active or symptomatic metastases of CNS, carcinomatous meningitis or leptomeningeal disease indicated by known clinical symptoms, cerebral edema and/or progressive neoplasia. Patients with history of CNS metastasis or compression of the spinal cord are eligible if they have received local final treatment (e.g., radiotherapy, stereotactic surgery) and if they have remained clinically stable without using anticonvulsants and corticosteroids for a minimum of 4 weeks prior to the first day of study treatment.\n* Refractory nauseas and vomiting, chronic gastrointestinal disease, inability to swallow study drug or significant intestinal resection that restricts the adequate absorption of osimertinib (AZD9291).\n* Patients who have had a surgical procedure unrelated to the study within 7 days prior to the administration of the drug or a significant traumatic lesion during the 4 weeks prior to starting the administration of the study drug, patients who have not recovered from the side effects of any major surgery or patients who might need major surgery during the course of the study.\n* Pregnant or breastfeeding women. Women of childbearing potential, including women who had their last menstrual period within the last two years, must have a negative serum or urine pregnancy test in the 7 days prior to the start of the treatment.\n* Patients who are not willing to use an adequate contraception method until 12 months after the last dose of study treatment.\n* Patients with a serious concomitant systemic disorder (e.g., active infection, including HIV or heart disease) that is incompatible with the study (in the opinion of the investigator), history of bleeding diathesis or anticoagulant therapy (the use of low molecular weight heparin is permitted provided that it is used for prophylaxis).\n* Patients with a history of cancer that has been completely treated, with no evidence of malignant disease currently cannot be enrolled in the study if their chemotherapy was completed less than 6 months prior and/or have received a bone marrow transplant less than 2 years before the first day of study treatment.\n* Prior treatment with cytotoxic chemotherapy for advanced NSCLC; neoadjuvant/adjuvant chemotherapy is permitted if at least 6 months have elapsed between the end of chemotherapy and the first day of study treatment.\n* Patients who have received prior EGFR treatments for lung cancer.\n* Patients who have received treatment with an investigational drug within 3 weeks before the first day of study treatment.\n* Treatment with prohibited drugs within 14 days before the first day of study treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Rafael Rosell, MD, PhD","affiliation":"Catalan Institute of Oncology, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"MedSIR Investigative Site","city":"A Coruña","zip":"15706","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"MedSIR Investigative Site","city":"Barcelona","zip":"08026","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"MedSIR Investigative Site","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"MedSIR Investigative Site","city":"Bilbao","zip":"48903","country":"Spain","geoPoint":{"lat":43.26271,"lon":-2.92528}},{"facility":"MedSIR Investigative Site","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"MedSIR Investigative Site","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"MedSIR Investigative Site","city":"Valencia","zip":"46015","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"referencesModule":{"references":[{"pmid":"34763195","type":"DERIVED","citation":"Majem M, Sullivan I, Viteri S, Lopez-Vivanco G, Cobo M, Sanchez JM, Garcia-Gonzalez J, Garde J, Sampayo M, Martrat G, Malfettone A, Karachaliou N, Molina-Vila MA, Rosell R. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. Eur J Cancer. 2021 Dec;159:174-181. doi: 10.1016/j.ejca.2021.09.039. Epub 2021 Nov 8."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Fifty-one patients were screened of whom 22 patients with advanced NSCLC harbouring pre-treatment sensitising EGFR and Thr790Met mutations were enrolled and started to receive first-line osimertinib.","groups":[{"id":"FG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"22"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"9"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"22"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"9"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"13"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"13"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}]}]},{"title":"Smoking history","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Never","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]},{"title":"Former","categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}]}]},{"title":"Tumor stage","description":"Tumor stage was assessed at baseline according to TNM classification version 7, in which higher grades are correlated with worse outcomes.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"IV","categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}]}]},{"title":"Central nervous system metastases","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}]}]},{"title":"EGFR sensitizing mutation","description":"EGFR mutation testing was determined in tissue and blood samples using a Taqman assay. For sensitizing mutations, a tissue sample was considered positive if the two cell extracts collected were positive. In blood samples, analyses were performed using two samples of serum and/or two samples of plasma cfDNA per patient.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Ex19del","categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]},{"title":"Thr790Met","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Leu858Arg","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]}]},{"title":"Tissue EGFR sensitizing mutation","description":"EGFR mutation testing was determined in tissue samples using a Taqman assay. For sensitizing mutations, a tissue sample was considered positive if the two cell extracts collected were positive.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Gly719X","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"Ex19del","categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}]},{"title":"Thr790Met","categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}]},{"title":"Leu858Arg","categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"Defined as the percentage of patients who achieved complete response \\[CR\\] and partial response \\[PR\\] to treatment in accordance to the revised RECIST guidelines (version 1.1) for target lesions: CR, disappearance of all target lesions; PR: at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of patients","timeFrame":"Through study completion. From baseline up to approximately 28 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","lowerLimit":"54.6","upperLimit":"89.3"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Time from the start of treatment to the time of death due to any cause.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Through study completion. From baseline up to 41 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.39","lowerLimit":"25.62","upperLimit":"NA","comment":"The median survival of 28.39 months was reached during the study; however, the upper limit of the confidence interval is not available due to an insufficient number of participants with events beyond the median value. Patients who had not experienced the event were censored at their last known follow-up date. This limitation arises because the calculation of the upper limit requires a sufficient number of events after the median, which was not the case in this study."}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"Time from the first documented response to documented disease progression or death, in accordance with RECIST 1.1 criteria.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Through study completion. From baseline up to 41 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"11.2","upperLimit":"NA","comment":"The upper limit of the confidence interval for the median Duration of Response (DoR) could not be determined due to an insufficient number of participants with events beyond the observed median."}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"Percentage of patients with complete response, partial response or stable disease for a minimum of 24 weeks, assessed in accordance with the modified Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, during all study period from baseline up to 78 weeks from the time of the first administration dose","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Through study completion. From baseline up to 41 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]}]},{"type":"SECONDARY","title":"Tumor Shrinkage","description":"Number of patients that presented tumor shrinkage","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Through study completion. From baseline up to 41 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}]},{"type":"SECONDARY","title":"Overall Plasma EGFR Mutation Status at Baseline","description":"Percentage of patients with a positive sensitizing EGFR mutation in plasma at baseline","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}]},{"type":"SECONDARY","title":"Overall Plasma Acquired Resistance to Osimertinib (AZD9291)","description":"Percentage of patients who develop anti-drug mutations in plasma","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Through study completion. From baseline up to 41 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 3 or 4 Adverse Events and SAEs","description":"Patient safety and adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) of the U.S. National Cancer Institute (NCI), version 4. Adverse event(s) are those which, according to the protocol or in the opinion of the investigator, can cause serious or permanent damage or which rule out further treatment with the study drug. Grade 3 means severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 means life-threatening consequences; urgent intervention indicated.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Through study completion. From baseline up to 41 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Defined as the period of time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Through study completion. From baseline up to 41 months.","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"14.1","upperLimit":"NA","comment":"The median progression-free survival (PFS) was 23.1 months; however, the upper limit of the confidence interval is not available due to an insufficient number of participants who experienced disease progression or death beyond the median value. Patients who had not progressed or died at the time of analysis were censored at their last evaluable assessment."}]}]}]},{"type":"SECONDARY","title":"Overall Plasma EGFR Mutation Status at Two Weeks After the First Study Dose","description":"Measured by percentage of patients with a positive sensitizing EGFR mutation in plasma two weeks after the first study dose","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Two weeks after the first study dose","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}]},{"type":"SECONDARY","title":"Overall Plasma EGFR Mutation Status at Disease Progression","description":"Measured by percentage of patients with a positive sensitizing EGFR mutation in plasma at disease progression","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At the time of disease progression confirmed radiologically or clinically, up to 78 weeks","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}]},{"type":"SECONDARY","title":"Plasma EGFR Thr790Met Mutation Status at Baseline","description":"Measured by percentage of patients with EGFR Thr790Met mutation in plasma at baseline","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At baseline","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Plasma EGFR Thr790Met Mutation Status at Two Weeks After the First Study Dose","description":"Measured by percentage of patients with EGFR Thr790Met mutation in plasma at two weeks after the first study dose","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Two weeks after the first study dose","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Plasma EGFR Thr790Met Mutation Status at Disease Progression","description":"Measured by percentage of patients with EGFR Thr790Met mutation in plasma at disease progression","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At the time of disease progression confirmed radiologically or clinically, up to 78 weeks","groups":[{"id":"OG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"42 months","description":"Regular investigator and local laboratory assessments were used to determine adverse events. Basic safety visits were performed on day 1 of each cycle every 2 cycles (every 6 weeks).","eventGroups":[{"id":"EG000","title":"Osimertinib","description":"The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.\n\nOsimertinib: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.","deathsNumAffected":1,"deathsNumAtRisk":22,"seriousNumAffected":10,"seriousNumAtRisk":22,"otherNumAffected":22,"otherNumAtRisk":22}],"seriousEvents":[{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Elevated creatine phosphokinase levels in blood","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Limb pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Disease worsening","organSystem":"General disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Femur fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Gastrointestinal hypomotility","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Paralytic ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Pulmonary infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Heart failure","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Peripheral ischemia","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Psychotic disorders","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":22}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":22}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":22}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":22}]},{"term":"Anorexia","organSystem":"General disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":22}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":22}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22}]},{"term":"Alopecia","organSystem":"General disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22}]},{"term":"Dry mouth","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":22}]},{"term":"Mucosa inflammation","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Muscle spasm","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Insomnia","organSystem":"General disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Dizziness","organSystem":"General disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":22}]},{"term":"Itching","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Dry nose","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Ungual toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22}]},{"term":"Sensory disturbances","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Cold","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Congested nose","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Exertional dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Edema","organSystem":"General disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Urinary tract infections","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]},{"term":"Elevated transaminase levels","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE v.4.0.","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Rafael Rosell","organization":"Catalan Institute of Oncology, Institut d'Investigació en Ciències, de la Salut Germans Trias i Pujol","email":"rrosell@iconcologia.net","phone":"+34 935 543 050"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-05-21","uploadDate":"2022-02-10T05:47","filename":"Prot_000.pdf","size":370934},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-05-03","uploadDate":"2022-02-10T05:48","filename":"SAP_001.pdf","size":658737}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000596361","term":"osimertinib"}]}},"hasResults":true}